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Background: Delirium in older adults is a common and serious acute neuropsychiatric syndrome, with core
features of inattention and global cognitive impairment. Although antipsychotic drugs are the medications most
frequently used to treat this syndrome, these drugs are associated with a variety of adverse events, including
sedation, extrapyramidal side effects, and cardiac arrhythmias.
Methods: We report on two cases in which monotherapy of the selective serotonin reuptake inhibitor and sigma-
1 receptor agonist fluvoxamine was effective in ameliorating the delirium of patients with Alzheimer’s disease.
Results: Delirium Rating Scale (DRS) scores in the two patients with Alzheimer’s disease decreased after
fluvoxamine monotherapy.
Conclusion: Doctors should consider that fluvoxamine could be an alternative approach in treating delirium in
patients with Alzheimer’s disease because of the risk of extrapyramidal side effects by antipsychotic drugs.
Background
Delirium in older adults is a common and serious acute
neuropsychiatric syndrome, with core features of inat-
tention and global cognitive impairment [1]. Antipsy-
chotic drugs are the medications most frequently used
to treat this syndrome, although exposure to these drugs
can itself pose a risk for the subsequent development of
delirium. Furthermore, antipsychotic drugs are asso-
ciated with a variety of adverse events, including seda-
tion, extrapyramidal side effects, and cardiac
arrhythmias. Although the pathophysiology of delirium
is not fully understood, current evidence suggests that
drug toxicity, inflammation and acute stress responses
can all contribute to a disruption of neurotransmission
(for example, acetylcholine, glutamate, g-aminobutyric
acid, dopamine, serotonin, norepinephrine) and, ulti-
mately, to the development of delirium [1].
The endoplasmic reticulum protein sigma-1 receptors
play a key role in Ca
2+ signalling and cell survival, and
have been shown to regulate a number of neurotrans-
mitter systems in the brain [2-6]. The selective serotonin
reuptake inhibitor (SSRI) fluvoxamine is a very potent
agonist at sigma-1 receptors, which are also implicated
in cognition and the pathophysiology of neuropsychia-
tric diseases [2-6]. A study using the selective sigma-1
receptor agonist [
11C]-SA4503 and positron emission
tomography demonstrated that fluvoxamine binds to
sigma-1 receptors in living human brain at therapeutic
doses, suggesting that sigma-1 receptors might play a
role in the mechanism of action of fluvoxamine [7].
Given the role of sigma-1 receptors in the regulation
of neurotransmitter systems, we hypothesised that flu-
voxamine might be effective in the treatment of delir-
ium. Here we report two cases in which fluvoxamine




The patient was an 82-year-old Japanese woman who
was diagnosed with Alzheimer’s disease according to the
Diagnostic and Statistical Manual of Mental Disorders,
fourth edition (DSM-IV) and International Classification
of Diseases, 10th edition (ICD-10) criteria. Brain com-
puted tomography (CT), magnetic resonance imaging
(MRI), and single photon emission computed tomogra-
phy (SPECT) were also performed. Brain CT showed
brain atrophy and ventricular enlargement, and MRI
showed small infarcts in the brain. N-isopropyl- [
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123I]-IMP)-SPECT showed the
reduction of blood flow in the posterior cingulate cortex
and lateral occipital cortex. Since she has hypertension
and diabetes, antidiabetic and antihypertension treat-
ments were administered before the development of
delirium. She was hospitalised due to lung congestion
that was detected by chest radiography. Her sleep dis-
turbance was not improved by benzodiazepines, and she
developed visual hallucinations of something. A psychia-
tric consultation was scheduled, and revealed disorienta-
tion and memory deficits. Her Delirium Rating Scale
( D R S )[ 8 ]a n dM i n i - M e n t a lScale Examination (MMSE)
[9] scores were 17/32 and 20/30, respectively. Treatment
with fluvoxamine (25 mg) was initiated after dinner, and
next day increased to 50 mg. At 2 days after beginning
treatment with fluvoxamine, her DRS score had
decreased to 5/32, and both her delirium and sleep dis-
turbance improved.
Case 2
The patient was a 77-year-old Japanese woman who had
been diagnosed with Alzheimer’s disease according to
the DSM-IV and ICD-10 criteria. Brain CT, MRI, and
SPECT were also performed. Before the development of
delirium, she had been treated with olanzapine (5 mg)
because of her disorientation. She was hospitalised due
to her persecutory delusions. At the time of hospitalisa-
tion, her DRS and MMSE scores were 17/32 and 21/30,
respectively. Treatment with fluvoxamine (50 mg, twice
a day) was initiated, and the next day increased to 100
mg since there were no gastrointestinal side effects. Her
tendency to reject medication gradually improved 3 days
after beginning treatment with fluvoxamine. At 1 week
later, her DRS score had decreased to 8/32, and her
condition is currently stable.
Discussion
To our knowledge, this is the first report demonstrating
that fluvoxamine monotherapy is effective for treating
the delirium of patients with Alzheimer’s disease. None-
theless, a randomised double-blind, placebo-controlled
study of fluvoxamine will be needed to confirm its effi-
cacy for the treatment of this syndrome. In addition, it
is currently unclear whether sigma-1 receptors are
involved in the action of fluvoxamine on delirium. In
order to confirm the role of sigma-1 receptors in the
treatment of delirium, a randomised double-blind, pla-
cebo-controlled study of the selective sigma-1 receptor
agonists (for example, cutamesine (SA4503)) in patients
with delirium would also be of interest.
Previously, it has been reported that the combination
of SSRIs with antipsychotic drug(s) and concomitant
benztropine might increase the risk of delirium in
patients [10-13]. Byerly et al. [12] reported a case
showing delirium associated with sertraline, haloperidol
and benzotropine. Furthermore, Armstrong et al. [13]
reported a case of delirium in a patient who was taking
benztropine and paroxetine concomitantly. These
authors suggest that the addition of sertraline or paroxe-
tine may cause a clinically meaningful inhibition of
benztropine metabolism or an inhibition of central cho-
linergic function [12,13]. Nonetheless, the precise
mechanisms underlying the incidence of delirium asso-
ciated with the combination of sertraline (or paroxetine)
and benztropine are currently unclear. Recent findings
suggest that sigma-1 receptors might be involved in the
different mechanisms of some SSRIs [4]. Fluvoxamine is
a potent sigma-1 receptor agonist, and sertraline may be
a sigma-1 receptor antagonist [4-6,14-16]. Paroxetine is
a weak at sigma-1 receptors [4]. Taken together, it is
likely that the difference for pharmacological actions
(agonist or antagonist) of SSRIs at sigma-1 receptors
may be involved in the mechanisms of different effects
of these SSRIs [4-6] although a further detailed study is
necessary.
Delirium is regarded as syndrome that consists of sev-
eral domains of symptoms, such as disturbance of con-
sciousness, cognitions, and perceptions [17]. At present,
it is unclear whether fluvoxamine monotherapy is effec-
tive for certain domain of delirious symptoms or for all
symptoms equally. Given the role of sigma-1 receptors
in the cognition [4-6], it seems that improvement of
cognitive impairments by sigma-1 receptor agonist may
be involved in the mechanisms of this drug although a
further study will be necessary.
A previous meta-analysis of randomised placebo-con-
trolled trials demonstrated an elevated risk of mortality
in older patients with dementia who were treated with
atypical antipsychotics [18]. This paper suggests that the
widespread use of atypical antipsychotic drugs in older
adults should be re-evaluated, since older patients with
delirium may have dementia. Therefore, the sigma-1
receptor agonist fluvoxamine may serve as an alternative
treatment option for older adults with delirium.
Conclusions
These two cases suggest that fluvoxamine could be an
alternative approach in treating delirium of patients
with Alzheimer’s disease because of the risk of extrapyr-
amidal side effects by antipsychotic drugs. More detailed
double-blind studies should be performed to clarify the
role of sigma-1 receptors in the efficacy of fluvoxamine
for delirium.
Consent
Written informed consent was obtained from the all
patients in this case report.
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